{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-23-006898","form_type":"8-K","ticker":"COSM","cik":"0001474167","company_name":"Cosmos Health Inc.","filed_at":"2023-09-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.027138+00:00","generated_at":"2026-06-10T17:32:04.715738+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Cosmos Health targets FY2026 revenue >$180M and EBITDA >$20M; recaps 2023 milestones","bullets":["Inaugural 2026 guidance: gross annual revenue over $180M and EBITDA exceeding $20M.","Completed three acquisitions in 2023: Cana Laboratories, I. Bikas GP assets, and ZipDoctor telehealth.","Nutraceutical brands Sky Premium Life and Mediterranation expanding into new sales channels and geographies.","Maintains robust balance sheet with negligible debt; CEO's personal investment now exceeds $15M.","Second phase of obesity product CCX0722 completed; clinical trials scheduled to start in Q4 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-23-006898","json":"https://secwatch.observer/filing/0001477932-23-006898.json","markdown":"https://secwatch.observer/filing/0001477932-23-006898.md","text":"https://secwatch.observer/filing/0001477932-23-006898.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1474167/000147793223006898/0001477932-23-006898-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1474167/000147793223006898/cosm_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T17:32:04.715738+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}